Notice on Convening the 2nd Extraordinary General Meeting in 2025
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Notice on Convening the 2nd Extraordinary General Meeting in 2025
Filed with SSE · · 9 pages · Chinese
Release
Youcare Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Youcare Pharmaceutical
- Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the FDA
- Announcement on Resignation of Independent Director
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Indicative Announcement on Completion of Transfer Registration for Partial Shares Held by Controlling Shareholders Subject to Judicial Auction and Change in Equity Shares Exceeding Integer Multiple of 5%
- Announcement on Voluntary Disclosure of Subsidiary’s YKYY029 Injection Obtaining Clinical Trial Approval from the FDA
Later from Youcare Pharmaceutical
- Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
- Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
- Announcement on Voluntary Disclosure of Subholding YKYY018 Inhalation Aerosol's FDA Clinical Trial Approval
- Announcement on Voluntary Disclosure of Subsidiary’s YKYY018 Inhalation Aerosol Obtaining Clinical Trial Approval from the National Medical Products Administration
- Announcement on Appointment of an Additional Director and Adjustment of Members of Special Committees of the Board of Directors
Follow Youcare Pharmaceutical into a list and get an email when it puts out news.
Follow Youcare Pharmaceutical